CHEN Sheng-Yun, WANG Dan-Dan, YANG Zhong-Hua, et al.. The Application of Alteplase via Vein in the Treatment of Acute Ischemic Stroke[J]. Chinese Journal of Stroke, 2016, 11(10): 821-823.
1 Wang Y，Liao X，Zhao X，et al. Using recombinanttissue plasminogen activator to treat acute ischemicstroke in China：analysis of the results from theChinese National Stroke Registry (CNSR)[J]. Stroke，2011，42：1658-1664.2 Johnston SC，Mendis S，Mathers CD. Globalvariation in stroke burden and mortality：estimatesfrom monitoring，surveillance，and modelling[J].Lancet Neurol，2009，8：345-354.3 Wang YL，Wu D，Liao X，et al. Burden of stroke inChina[J]. Int J Stroke，2007，2：211-213.4 Liu M，Wu B，Wang WZ，et al. Stroke in China：epidemiology，prevent ion，and managementstrategies[J]. Lancet Neurol，2007，6：456-464.5 The National Institute of Neurological Disorders andStroke rt-PA Stroke Study Group. Tissue plasminogenactivator for acute ischemic stroke[J]. N Engl J Med，1995，333：1581-1587.6 Demaerschalk BM，Kleindorfer DO，Adeoye OM，etal. Scientific rationale for the inclusion and exclusioncriteria for intravenous alteplase in acute ischemicstroke：a statement for healthcare professionals fromthe American Heart Association/American StrokeAssociation[J]. Stroke，2016，47：581-641.7 Berge E，Cohen G，Roaldsen MB，et al. Effects ofalteplase on survival after ischaemic stroke (IST-3)：3year follow-up of a randomised，controlled，openlabeltrial[J]. Lancet Neurol，2016，15：1028-1034.8 Phan TG，Clissold B，Ly J，et al. Stroke severityand comorbidity index for prediction of mortalityafter ischemic stroke from the virtual internationalstroke trials archive-acute collaboration[J]. J StrokeCerebrovasc Dis，2016，25：835-842.9 Ma z ya MV，Le e s KR，Co l l a s D，e t a l . IVthrombolysis in very severe and severe ischemic stroke：Results from the SITS-ISTR Registry[J]. Neurology，2015，85：2098-2106.10 Song D，Cho AH. Previous and recent evidence ofendovascular therapy in acute ischemic stroke[J].Neurointervention，2015，10：51-59.
